Please login to the form below

Not currently logged in
Email:
Password:

Besponsa

This page shows the latest Besponsa news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m

Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m

Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m. ... Following approval in Scotland in June, it is estimated that more than 120 people across the UK are now eligible to

Latest news

  • NICE to look again at Pfizer’s Besponsa after appeal NICE to look again at Pfizer’s Besponsa after appeal

    NICE to look again at Pfizer’ s Besponsa after appeal. The blood cancer medicine was originally turned down on cost-effectiveness grounds. ... UK practice, however, would largely consist of using [Besponsa] as a step to enable patients to have a stem

  • NICE set to reject Pfizer's leukaemia drug Besponsa NICE set to reject Pfizer's leukaemia drug Besponsa

    NICE set to reject Pfizer's leukaemia drug Besponsa. Firm plans to appeal the final appraisal determination on its orphan drug. ... The National Institute of Healthcare and Excellence (NICE) is set to reject Pfizer’s orphan drug for leukaemia Besponsa

  • FDA clears Pfizer's leukaemia drug Besponsa FDA clears Pfizer's leukaemia drug Besponsa

    FDA clears Pfizer's leukaemia drug Besponsa. The breakthrough treatment is the first CD22-targeted ADC to be approved in the US. ... Besponsa has been approved with a boxed warning for hepatotoxicity and an increased risk of post-hematopoietic stem cell

  • NICE rejects Pfizer's antibody drug for leukaemia NICE rejects Pfizer's antibody drug for leukaemia

    NICE rejects Pfizer's antibody drug for leukaemia. Trial shows no survival benefit from Besponsa compared to current treatment. ... The National Institute for Health and Care Excellence (NICE) has turned down Pfizer’s leukaemia drug Besponsa in draft

  • CHMP backs two rare disease therapies at April meeting CHMP backs two rare disease therapies at April meeting

    In other news from the CHMP meeting, Pfizer picked up a positive opinion for Besponsa (inotuzumab ozogamicin) as a single-agent treatment for adults with relapsed or refractory CD22-positive

More from news
Approximately 4 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics